CA3016588A1 - Methods and compositions for treatment of zika virus infection - Google Patents
Methods and compositions for treatment of zika virus infection Download PDFInfo
- Publication number
- CA3016588A1 CA3016588A1 CA3016588A CA3016588A CA3016588A1 CA 3016588 A1 CA3016588 A1 CA 3016588A1 CA 3016588 A CA3016588 A CA 3016588A CA 3016588 A CA3016588 A CA 3016588A CA 3016588 A1 CA3016588 A1 CA 3016588A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- subject
- dose
- zika virus
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract 69
- 208000001455 Zika Virus Infection Diseases 0.000 title claims abstract 12
- 208000035332 Zika virus disease Diseases 0.000 title claims abstract 12
- 208000020329 Zika virus infectious disease Diseases 0.000 title claims abstract 12
- 239000000203 mixture Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 241000907316 Zika virus Species 0.000 claims 10
- 210000001124 body fluid Anatomy 0.000 claims 6
- 210000000582 semen Anatomy 0.000 claims 6
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 4
- 238000012423 maintenance Methods 0.000 claims 4
- 238000007911 parenteral administration Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 210000004381 amniotic fluid Anatomy 0.000 claims 3
- 230000005540 biological transmission Effects 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 3
- 210000003756 cervix mucus Anatomy 0.000 claims 3
- 210000003754 fetus Anatomy 0.000 claims 3
- 210000004251 human milk Anatomy 0.000 claims 3
- 235000020256 human milk Nutrition 0.000 claims 3
- 210000001161 mammalian embryo Anatomy 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000003296 saliva Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000002826 placenta Anatomy 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 241000256111 Aedes <genus> Species 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 241000255925 Diptera Species 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 206010025482 malaise Diseases 0.000 claims 1
- 208000004141 microcephaly Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304317P | 2016-03-06 | 2016-03-06 | |
| US62/304,317 | 2016-03-06 | ||
| US201662324180P | 2016-04-18 | 2016-04-18 | |
| US62/324,180 | 2016-04-18 | ||
| US201662368111P | 2016-07-28 | 2016-07-28 | |
| US62/368,111 | 2016-07-28 | ||
| US201662370697P | 2016-08-03 | 2016-08-03 | |
| US62/370,697 | 2016-08-03 | ||
| US201662411867P | 2016-10-24 | 2016-10-24 | |
| US62/411,867 | 2016-10-24 | ||
| US201662414466P | 2016-10-28 | 2016-10-28 | |
| US62/414,466 | 2016-10-28 | ||
| US201762462852P | 2017-02-23 | 2017-02-23 | |
| US62/462,852 | 2017-02-23 | ||
| PCT/US2017/020961 WO2017155886A1 (en) | 2016-03-06 | 2017-03-06 | Methods and compositions for treatment of zika virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3016588A1 true CA3016588A1 (en) | 2017-09-14 |
Family
ID=59789791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3016588A Pending CA3016588A1 (en) | 2016-03-06 | 2017-03-06 | Methods and compositions for treatment of zika virus infection |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10512649B2 (enExample) |
| EP (1) | EP3426659A4 (enExample) |
| JP (1) | JP7046015B2 (enExample) |
| AU (1) | AU2017229105B2 (enExample) |
| CA (1) | CA3016588A1 (enExample) |
| MA (1) | MA43812A (enExample) |
| MX (1) | MX381542B (enExample) |
| TW (1) | TWI767903B (enExample) |
| WO (1) | WO2017155886A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7416445B2 (ja) * | 2019-02-18 | 2024-01-17 | 株式会社栄養・病理学研究所 | ブタにおけるｔ細胞の活性化度を評価する方法、ブタにおけるｔ細胞活性化を評価する剤、ブタｔ細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| US6228741B1 (en) | 1998-01-13 | 2001-05-08 | Texas Instruments Incorporated | Method for trench isolation of semiconductor devices |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| US7098334B2 (en) | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| US7560434B2 (en) | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| ES2362805T3 (es) | 2006-09-07 | 2011-07-13 | Industrial Research Limited | Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas. |
| MX2009002707A (es) | 2006-09-11 | 2009-11-26 | Southern Res Inst | Nucleosidos de azoles y su utilizacion como inhibidores de arn y adn polimerasas virales. |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| EP2627334B1 (en) | 2010-10-15 | 2015-04-29 | Biocryst Pharmaceuticals, Inc. | Compositions for use in the treatment of viral infections |
-
2017
- 2017-03-06 JP JP2018566196A patent/JP7046015B2/ja active Active
- 2017-03-06 AU AU2017229105A patent/AU2017229105B2/en active Active
- 2017-03-06 TW TW106107257A patent/TWI767903B/zh active
- 2017-03-06 CA CA3016588A patent/CA3016588A1/en active Pending
- 2017-03-06 EP EP17763837.6A patent/EP3426659A4/en active Pending
- 2017-03-06 MX MX2018010707A patent/MX381542B/es unknown
- 2017-03-06 US US16/082,437 patent/US10512649B2/en active Active
- 2017-03-06 MA MA043812A patent/MA43812A/fr unknown
- 2017-03-06 WO PCT/US2017/020961 patent/WO2017155886A1/en not_active Ceased
-
2019
- 2019-11-22 US US16/692,816 patent/US10933066B2/en active Active
-
2021
- 2021-03-01 US US17/188,814 patent/US11975003B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10512649B2 (en) | 2019-12-24 |
| US11975003B2 (en) | 2024-05-07 |
| US20210186976A1 (en) | 2021-06-24 |
| US10933066B2 (en) | 2021-03-02 |
| AU2017229105A1 (en) | 2018-10-11 |
| JP2019507195A (ja) | 2019-03-14 |
| EP3426659A4 (en) | 2019-12-25 |
| EP3426659A1 (en) | 2019-01-16 |
| WO2017155886A1 (en) | 2017-09-14 |
| US20190083496A1 (en) | 2019-03-21 |
| TW201731515A (zh) | 2017-09-16 |
| MA43812A (fr) | 2018-11-28 |
| TWI767903B (zh) | 2022-06-21 |
| AU2017229105B2 (en) | 2021-08-12 |
| MX381542B (es) | 2025-03-04 |
| US20200085830A1 (en) | 2020-03-19 |
| JP7046015B2 (ja) | 2022-04-01 |
| MX2018010707A (es) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5902698B2 (ja) | ポリメラーゼの阻害のための方法および組成物 | |
| US20240269125A1 (en) | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent | |
| EP3854398B1 (en) | Favipiravir for use in the treatment of coronavirus infection | |
| CN101743008A (zh) | 用于治疗或预防登革热感染的抗病毒药 | |
| KR20120049852A (ko) | 뎅기 바이러스 감염의 치료 및 예방 | |
| KR20120044930A (ko) | 고병원성 감염성 질환의 예방 및 치료제 | |
| US20240261313A1 (en) | Kit for preventing or treating filovirus and flavivirus diseases | |
| RU2518314C2 (ru) | Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами | |
| US11975003B2 (en) | Methods and compositions for treatment of Zika virus infection | |
| CA2945825C (en) | Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues | |
| CN104203228A (zh) | 具有抗黄病毒的抗病毒活性的组合物 | |
| WO2020092193A1 (en) | Treatments for zika virus infection | |
| Wutzler et al. | Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports | |
| US20220409583A1 (en) | Treatment and Prevention of Dengue Disease | |
| CN114980885A (zh) | 治疗hiv-1感染的方法 | |
| Chen et al. | Tolvaptan, an FDA-approved drug, inhibits Zika virus infection both in vitro and in vivo. | |
| Ilgın et al. | Overview of Drugs used Against Zika Virus | |
| Ilgın et al. | Overview of Drugs used Against Zika Virus: An Overview | |
| WO2016089904A1 (en) | Trans-clomiphene and its analogues as agents for treating or preventing filovirus diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220307 |
|
| EEER | Examination request |
Effective date: 20220307 |
|
| EEER | Examination request |
Effective date: 20220307 |
|
| EEER | Examination request |
Effective date: 20220307 |
|
| EEER | Examination request |
Effective date: 20220307 |
|
| EEER | Examination request |
Effective date: 20220307 |
|
| EEER | Examination request |
Effective date: 20220307 |